TargetKappa-type opioid receptor(Cavia porcellus (domestic guinea pig))
Theravance Biopharma Us
Curated by ChEMBL
Theravance Biopharma Us
Curated by ChEMBL
Affinity DataKi: 0.0100nMAssay Description:Displacement of [3H]DPN from guinea pig kappa opioid receptor expressed in CHOK1 cell membranesMore data for this Ligand-Target Pair
TargetKappa-type opioid receptor(Cavia porcellus (domestic guinea pig))
Theravance Biopharma Us
Curated by ChEMBL
Theravance Biopharma Us
Curated by ChEMBL
Affinity DataKi: 0.0100nMAssay Description:Displacement of [3H]DPN from guinea pig kappa opioid receptor expressed in CHOK1 cell membranesMore data for this Ligand-Target Pair
Affinity DataKi: 0.0186nMAssay Description:Using the following procedure, varying concentration of compounds of the invention were assessed for their ability to inhibit c-Abl enzyme's phos...More data for this Ligand-Target Pair
Affinity DataKi: 0.0200nMAssay Description:Using the following procedure, varying concentration of compounds of the invention were assessed for their ability to inhibit c-Abl enzyme's phos...More data for this Ligand-Target Pair
Affinity DataKi: 0.0200nMAssay Description:Using the following procedure, varying concentration of compounds of the invention were assessed for their ability to inhibit c-Abl enzyme's phos...More data for this Ligand-Target Pair
Affinity DataKi: 0.0200nMAssay Description:Using the following procedure, varying concentration of compounds of the invention were assessed for their ability to inhibit c-Abl enzyme's phos...More data for this Ligand-Target Pair
Affinity DataKi: 0.0200nMAssay Description:Using the following procedure, varying concentration of compounds of the invention were assessed for their ability to inhibit c-Abl enzyme's phos...More data for this Ligand-Target Pair
Affinity DataKi: 0.0200nMAssay Description:Using the following procedure, varying concentration of compounds of the invention were assessed for their ability to inhibit c-Abl enzyme's phos...More data for this Ligand-Target Pair
Affinity DataKi: 0.0200nMAssay Description:Using the following procedure, varying concentration of compounds of the invention were assessed for their ability to inhibit c-Abl enzyme's phos...More data for this Ligand-Target Pair
Affinity DataKi: 0.0200nMAssay Description:Using the following procedure, varying concentration of compounds of the invention were assessed for their ability to inhibit c-Abl enzyme's phos...More data for this Ligand-Target Pair
Affinity DataKi: 0.0300nMAssay Description:Using the following procedure, varying concentration of compounds of the invention were assessed for their ability to inhibit c-Abl enzyme's phos...More data for this Ligand-Target Pair
Affinity DataKi: 0.0300nMAssay Description:Using the following procedure, varying concentration of compounds of the invention were assessed for their ability to inhibit c-Abl enzyme's phos...More data for this Ligand-Target Pair
Affinity DataKi: 0.0300nMAssay Description:Using the following procedure, varying concentration of compounds of the invention were assessed for their ability to inhibit c-Abl enzyme's phos...More data for this Ligand-Target Pair
Affinity DataKi: 0.0300nMAssay Description:Using the following procedure, varying concentration of compounds of the invention were assessed for their ability to inhibit c-Abl enzyme's phos...More data for this Ligand-Target Pair
Affinity DataKi: 0.0300nMAssay Description:Using the following procedure, varying concentration of compounds of the invention were assessed for their ability to inhibit c-Abl enzyme's phos...More data for this Ligand-Target Pair
Affinity DataKi: 0.0300nMAssay Description:Using the following procedure, varying concentration of compounds of the invention were assessed for their ability to inhibit c-Abl enzyme's phos...More data for this Ligand-Target Pair
Affinity DataKi: 0.0300nMAssay Description:Using the following procedure, varying concentration of compounds of the invention were assessed for their ability to inhibit c-Abl enzyme's phos...More data for this Ligand-Target Pair
Affinity DataKi: 0.0300nMAssay Description:Using the following procedure, varying concentration of compounds of the invention were assessed for their ability to inhibit c-Abl enzyme's phos...More data for this Ligand-Target Pair
Affinity DataKi: 0.0300nMAssay Description:Using the following procedure, varying concentration of compounds of the invention were assessed for their ability to inhibit c-Abl enzyme's phos...More data for this Ligand-Target Pair
Affinity DataKi: 0.0400nMAssay Description:Using the following procedure, varying concentration of compounds of the invention were assessed for their ability to inhibit c-Abl enzyme's phos...More data for this Ligand-Target Pair
Affinity DataKi: 0.0400nMAssay Description:Using the following procedure, varying concentration of compounds of the invention were assessed for their ability to inhibit c-Abl enzyme's phos...More data for this Ligand-Target Pair
Affinity DataKi: 0.0400nMAssay Description:Using the following procedure, varying concentration of compounds of the invention were assessed for their ability to inhibit c-Abl enzyme's phos...More data for this Ligand-Target Pair
Affinity DataKi: 0.0400nMAssay Description:Using the following procedure, varying concentration of compounds of the invention were assessed for their ability to inhibit c-Abl enzyme's phos...More data for this Ligand-Target Pair
Affinity DataKi: 0.0500nMAssay Description:Using the following procedure, varying concentration of compounds of the invention were assessed for their ability to inhibit c-Abl enzyme's phos...More data for this Ligand-Target Pair
Affinity DataKi: 0.0500nMAssay Description:Using the following procedure, varying concentration of compounds of the invention were assessed for their ability to inhibit c-Abl enzyme's phos...More data for this Ligand-Target Pair
Affinity DataKi: 0.0500nMAssay Description:Using the following procedure, varying concentration of compounds of the invention were assessed for their ability to inhibit c-Abl enzyme's phos...More data for this Ligand-Target Pair
Affinity DataKi: 0.0600nMAssay Description:Using the following procedure, varying concentration of compounds of the invention were assessed for their ability to inhibit c-Abl enzyme's phos...More data for this Ligand-Target Pair
Affinity DataKi: 0.0600nMAssay Description:Using the following procedure, varying concentration of compounds of the invention were assessed for their ability to inhibit c-Abl enzyme's phos...More data for this Ligand-Target Pair
Affinity DataKi: 0.0700nMAssay Description:Using the following procedure, varying concentration of compounds of the invention were assessed for their ability to inhibit c-Abl enzyme's phos...More data for this Ligand-Target Pair
Affinity DataKi: 0.0700nMAssay Description:Using the following procedure, varying concentration of compounds of the invention were assessed for their ability to inhibit c-Abl enzyme's phos...More data for this Ligand-Target Pair
Affinity DataKi: 0.0700nMAssay Description:Using the following procedure, varying concentration of compounds of the invention were assessed for their ability to inhibit c-Abl enzyme's phos...More data for this Ligand-Target Pair
Affinity DataKi: 0.0700nMAssay Description:Using the following procedure, varying concentration of compounds of the invention were assessed for their ability to inhibit c-Abl enzyme's phos...More data for this Ligand-Target Pair
Affinity DataKi: 0.0700nMAssay Description:Using the following procedure, varying concentration of compounds of the invention were assessed for their ability to inhibit c-Abl enzyme's phos...More data for this Ligand-Target Pair
Affinity DataKi: 0.0709nMAssay Description:Using the following procedure, varying concentration of compounds of the invention were assessed for their ability to inhibit c-Abl enzyme's phos...More data for this Ligand-Target Pair
Affinity DataKi: 0.0723nMAssay Description:Using the following procedure, varying concentration of compounds of the invention were assessed for their ability to inhibit c-Abl enzyme's phos...More data for this Ligand-Target Pair
Affinity DataKi: 0.0799nMAssay Description:Using the following procedure, varying concentration of compounds of the invention were assessed for their ability to inhibit c-Abl enzyme's phos...More data for this Ligand-Target Pair
Affinity DataKi: 0.0799nMAssay Description:Using the following procedure, varying concentration of compounds of the invention were assessed for their ability to inhibit c-Abl enzyme's phos...More data for this Ligand-Target Pair
Affinity DataKi: 0.0800nMAssay Description:Using the following procedure, varying concentration of compounds of the invention were assessed for their ability to inhibit c-Abl enzyme's phos...More data for this Ligand-Target Pair
Affinity DataKi: 0.0841nMAssay Description:Using the following procedure, varying concentration of compounds of the invention were assessed for their ability to inhibit c-Abl enzyme's phos...More data for this Ligand-Target Pair
Affinity DataKi: 0.0841nMAssay Description:Using the following procedure, varying concentration of compounds of the invention were assessed for their ability to inhibit c-Abl enzyme's phos...More data for this Ligand-Target Pair
Affinity DataKi: 0.0896nMAssay Description:Using the following procedure, varying concentration of compounds of the invention were assessed for their ability to inhibit c-Abl enzyme's phos...More data for this Ligand-Target Pair
Affinity DataKi: 0.0900nMAssay Description:Using the following procedure, varying concentration of compounds of the invention were assessed for their ability to inhibit c-Abl enzyme's phos...More data for this Ligand-Target Pair
Affinity DataKi: 0.0900nMAssay Description:Using the following procedure, varying concentration of compounds of the invention were assessed for their ability to inhibit c-Abl enzyme's phos...More data for this Ligand-Target Pair
Affinity DataKi: 0.0900nMAssay Description:Using the following procedure, varying concentration of compounds of the invention were assessed for their ability to inhibit c-Abl enzyme's phos...More data for this Ligand-Target Pair
Affinity DataKi: 0.0900nMAssay Description:Using the following procedure, varying concentration of compounds of the invention were assessed for their ability to inhibit c-Abl enzyme's phos...More data for this Ligand-Target Pair
Affinity DataKi: 0.0900nMAssay Description:Using the following procedure, varying concentration of compounds of the invention were assessed for their ability to inhibit c-Abl enzyme's phos...More data for this Ligand-Target Pair
Affinity DataKi: 0.0900nMAssay Description:Using the following procedure, varying concentration of compounds of the invention were assessed for their ability to inhibit c-Abl enzyme's phos...More data for this Ligand-Target Pair
Affinity DataKi: 0.0900nMAssay Description:Using the following procedure, varying concentration of compounds of the invention were assessed for their ability to inhibit c-Abl enzyme's phos...More data for this Ligand-Target Pair
TargetKappa-type opioid receptor(Cavia porcellus (domestic guinea pig))
Theravance Biopharma Us
Curated by ChEMBL
Theravance Biopharma Us
Curated by ChEMBL
Affinity DataKi: 0.100nMAssay Description:Displacement of [3H]DPN from guinea pig kappa opioid receptor expressed in CHOK1 cell membranesMore data for this Ligand-Target Pair
Affinity DataKi: 0.100nMAssay Description:Using the following procedure, varying concentration of compounds of the invention were assessed for their ability to inhibit c-Abl enzyme's phos...More data for this Ligand-Target Pair